NCT04728711

A Double Masked, Placebo Controlled, Single Center, Randomized Clinical Trial to Assess the Safety and Efficacy of Subjects With Mild Asthma Induced by the Bronchial Allergen Challenge (BAC)

A Double Masked, Placebo Controlled, Single Center, Randomized Clinical Trial to Assess the Safety and Efficacy of ADX-629 in Subjects With Mild Asthma Induced by the Bronchial Allergen Challenge (BAC)

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 8 (actual)
• Sponsor: Aldeyra Therapeutics, Inc. · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

A Double Masked, Placebo Controlled, Single Center, Randomized Clinical Trial to Assess the Safety and Efficacy of ADX-629 in Subjects with Mild Asthma Induced by the Bronchial Allergen Challenge (BAC)

Conditions

• Atopic Asthma

Interventions

Type	Name	Description
DRUG	ADX-629	ADX-629, 600 mg administered orally twice daily (PO bid) for a minimum of 1 week
DRUG	Placebo	Placebo, 600 mg administered orally twice daily (PO bid) for minimum 1 week

Timeline

• Start date: 2021-01-09
• Primary completion: 2022-01-18
• Completion: 2022-01-18
• First posted: 2021-01-28
• Last updated: 2025-02-17
• Results posted: 2025-02-17

Locations

1 site across 1 country: Canada

Regulatory

• FDA-regulated drug study